These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1457085)

  • 1. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension.
    Shieh SM; Sheu WH; Shen DC; Fuh MM; Chen YD; Reaven GM
    Am J Hypertens; 1992 Nov; 5(11):827-31. PubMed ID: 1457085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus.
    Maheux P; Facchini F; Jeppesen J; Greenfield MS; Clinkingbeard C; Chen YD; Reaven GM
    Am J Hypertens; 1994 May; 7(5):416-24. PubMed ID: 8060574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.
    Giorda C; Appendino M
    Metabolism; 1993 Nov; 42(11):1440-2. PubMed ID: 8231840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding.
    Dominguez LJ; Weinberger MH; Cefalu WT; Jacobs DB; Barbagallo M; Walsh MF; Sowers JR
    Am J Hypertens; 1995 May; 8(5 Pt 1):528-32. PubMed ID: 7662232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance.
    Shionoiri H; Ashino K; Yamanaka K; Shindo K; Hiroto S; Arita T
    Clin Ther; 1997; 19(3):527-36. PubMed ID: 9220217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
    Giordano M; Matsuda M; Sanders L; Canessa ML; DeFronzo RA
    Diabetes; 1995 Jun; 44(6):665-71. PubMed ID: 7789631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.
    Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM
    Am Heart J; 1996 Oct; 132(4):783-9. PubMed ID: 8831367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group.
    Lehtonen A
    Am Heart J; 1991 Apr; 121(4 Pt 2):1307-11. PubMed ID: 1826187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
    Levy D; Walmsley P; Levenstein M
    Am Heart J; 1996 May; 131(5):966-73. PubMed ID: 8615318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of a low fat diet and doxazosin on blood pressure control and blood lipids. Hunter Hypertension Research Group.
    J Hum Hypertens; 1994 Dec; 8(12):907-10. PubMed ID: 7884789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.
    Hobbs FR; Khan T; Collins B
    Br J Gen Pract; 2005 Jun; 55(515):437-43. PubMed ID: 15970067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension.
    Sheu WH; Swislocki AL; Hoffman B; Chen YD; Reaven GM
    Am J Hypertens; 1991 Mar; 4(3 Pt 1):199-205. PubMed ID: 2043298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of doxazosin and hydrochlorothiazide on lipid levels in Korean patients with essential hypertension.
    Jones DW; Sands CD
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):431-7. PubMed ID: 7504134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
    Huupponen R; Lehtonen A; Vähätalo M
    Eur J Clin Pharmacol; 1992; 43(4):365-8. PubMed ID: 1451714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
    Balabolkin MI; Khasanova ER; Trukhina TV; Kreminskaia VM
    Ter Arkh; 2002; 74(12):38-41. PubMed ID: 12577838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective alpha 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension.
    Yamasaki Y; Shiba Y; Sekiya M; Tsujino T; Hakui N; Kawamori R; Kamada T
    J Hum Hypertens; 1994 Aug; 8(8):555-8. PubMed ID: 7990080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension.
    Fuh MM; Shieh SM; Wu DA; Chen YD; Reaven GM
    Arch Intern Med; 1987 Jun; 147(6):1035-8. PubMed ID: 3296980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
    Courtney CH; McCance DR; Atkinson AB; Bassett J; Ennis CN; Sheridan B; Bell PM
    Metabolism; 2003 Sep; 52(9):1147-52. PubMed ID: 14506621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
    Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.